BHC (Bausch Health) Current Accrued Expense: $1,826 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BHC Bausch Health Companies Inc BHC
64 GF Score
Price $6.42
GF Value $7.47
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bausch Health Current Accrued Expense?

Bausch Health BHC +2.64% 64 Current Accrued Expense is $1,826 Mil as of Jun. 2026. GuruFocus rates BHC with a GF Score™ of 64/100 and a GF Value™ of $7.47 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Bausch Health's Current Accrued Expense for the quarter that ended in Jun. 2026 was $1,826 Mil.

Bausch Health's quarterly Current Accrued Expense declined from Dec. 2025 ($1,922 Mil) to Mar. 2026 ($1,837 Mil) and declined from Mar. 2026 ($1,837 Mil) to Jun. 2026 ($1,826 Mil).

Bausch Health's annual Current Accrued Expense increased from Dec. 2023 ($1,685 Mil) to Dec. 2024 ($1,974 Mil) but then declined from Dec. 2024 ($1,974 Mil) to Dec. 2025 ($1,922 Mil).

Bausch Health Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Bausch Health's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health Current Accrued Expense Chart

Bausch Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,718.00 1,618.00 1,685.00 1,974.00 1,922.00

Bausch Health Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,007.00 2,177.00 1,922.00 1,837.00 1,826.00
BHC
64GF Score
Bausch Health Companies Inc BHC
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch Health Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1,826 Mil mean?
Bausch Health (BHC) has a Current Accrued Expense of $1,826 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Bausch Health and its competitors.
Is Bausch Health's Current Accrued Expense too high?
Bausch Health's current Current Accrued Expense is $1,826 Mil. Overall, Bausch Health has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Current Accrued Expense compare to ZTS?
Bausch Health's Current Accrued Expense of $1,826 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Bausch Health and its competitors. Bausch Health's current Current Accrued Expense is $1,826 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.47, compared to a current price of $6.42 — trading 14.1% below its estimated fair value. The current Current Accrued Expense is $1,826 Mil. Bausch Health's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Bausch Health (BHC), the current Current Accrued Expense is $1,826 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch Health (BHC) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of $6.42 is trading 14.1% below its estimated GF Value™ of $7.47. GuruFocus considers Bausch Health to be Modestly Undervalued.

Key valuation signals for BHC:

  • Current Accrued Expense: $1,826 Mil
  • GF Value™: $7.47 vs. price of $6.42 (14.1% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
64GF Score

Get the complete analysis for BHC

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.42
Price
$7.47
GF Value